TransMolecular, Inc. Presentation at ARVO 2009

April 30, 2009

TransMolecular, Inc. announced that new information on the anti-angiogenic method-of-action of TM601 will be presented at ARVO. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including ophthalmic disease and cancer.

Poster # 1164/D1126 is titled, “TM601, a Peptide That Binds Annexin A2, Causes Regression of Choroidal Neovascularization (CNV),”

TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease. Most recently, the effects of TM601 on the neovasculature have also been validated in animal models of ophthalmic disease, including wet age-related macular degeneration (AMD).

Read the full release.

 

 

You might also enjoy...

Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/001019-transmolecular-inc-presentation-at-arvo-2009/trackback/

Have insights to contribute? Please submit your comment below